By Fineline Cube 
Sanofi (NASDAQ: SNY) reported full‑year 2025 revenues of EUR 43.626 billion (USD 47.8 billion), representing 9.9% growth at constant exchange rates (CER) and 6.2% on an actual basis, fueled by strong performance of Dupixent and new biopharma launches across major markets.
Key Financial Performance
| Metric | 2025 Result | CER Growth | Actual Growth |
|---|---|---|---|
| Total Revenue | EUR 43.626 B (USD 47.8 B) | +9.9% | +6.2% |
| 2026 Guidance | High single‑digit sales growth | — | — |
| Business EPS Growth | Slightly faster than sales | — | — |
Regional Performance & China Market
| Region | 2025 Sales (EUR) | USD Equivalent | CER Growth |
|---|---|---|---|
| United States | 22.176 billion | 24.3 billion | +16.3% |
| Europe | 9.169 billion | 10.1 billion | +1.6% |
| Rest of World | 12.281 billion | 13.4 billion | +5.6% |
| China (within RoW) | 2.621 billion | 2.9 billion | +2.0% |
China Growth Drivers: Diabetes medicines and other core therapies, partially offset by legacy product headwinds and national pricing mechanisms.
Key Growth Drivers
Dupixent Leads Portfolio
| Product | 2025 Sales (EUR) | USD Equivalent | CER Growth |
|---|---|---|---|
| Dupixent | 15.714 billion | 17.2 billion | +25.2% |
New Biopharma Launch Performance: EUR 3.91 billion (+47.9% CER)
| Product | 2025 Sales (EUR) | Growth |
|---|---|---|
| ALTUVIIIO | 1.16 billion | +77.6% |
| Sarclisa | 588 million | +28.5% |
| Nexviazyme/Nexviadyme | 790 million | +21.4% |
| Rezurock | 490 million | +8.7% |
| Ayvakit | 305 million | — |
Established Diabetes:
| Product | 2025 Sales (EUR) | Growth |
|---|---|---|
| Lantus | 1.73 billion | +10.3% |
| Toujeo | 1.35 billion | +12.0% |
Vaccines: EUR 7.936 billion (USD 8.7 billion), -1.2% due to timing of influenza and routine immunization programs.
Pipeline Progress & Outlook
2025 Regulatory Milestones:
- 10 approvals across immunology, rare diseases, and other therapeutic areas
- Positive Phase III data for amlitelimab in atopic dermatitis
2026 Guidance:
- High single‑digit sales growth expected
- Business EPS growth slightly outpacing top‑line performance
- CEO Paul Hudson: “We anticipate profitable growth to continue over at least five years.”
Forward‑Looking Statements
This brief contains forward‑looking statements regarding 2026 guidance, pipeline development, and market growth. Actual results may differ due to competitive dynamics, pricing pressures, and macroeconomic factors.-Fineline Info & Tech